| abstract |
A combination for the treatment of prostate cancer, comprising (i) one of a benzoheterocyclic compound, a pharmaceutically acceptable salt, a solvate, a polymorph, a co-crystal, a stereoisomer and an isotopic compound thereof, and (ii) an androgen receptor pathway modulator; wherein, the benzoheterocyclic compound is selected from the group consisting of: **(See formula)** and the androgen receptor pathway modulator is selected from: **(See formula)** |